Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH). For the study, published in Annals ...
Please provide your email address to receive an email when new articles are posted on . Descartes-08 is an autologous mRNA cell therapy indicated for many autoimmune diseases. The FDA granted the ...
A new study published in the Journal of the American Medical Association showed that for juvenile dermatomyositis (JDM), a combination of intermittent intravenous methylprednisolone pulse ...
What caused a 14-year-old girl to develop chronic, intractable light-sensitive skin eruptions on her face, upper body, and extremities? That's what Ruth Ann Vleugels, MD, MPH, of Harvard Medical ...
GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...
A team investigating the pediatric inflammatory disease juvenile dermatomyositis (JDM) has received a € 350,000 grant from the Prinses Beatrix Spierfonds (Dutch Neuromuscular Foundation) for the ...
IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...
Dermatomyositis is a rare autoimmune disease that typically affects the skin, muscle and respiratory system. Patients with dermatomyositis usually require prompt treatment with intense ...
Since patients with refractory Dermatomyositis (DM) may not respond to existing treatment options, there remains an unmet medical need for more therapeutic alternatives. There are now several drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results